Adult patients with moderate-to-severe atopic dermatitis who were treated with systemic agents, including cyclosporine, azathioprine, mycophenolate mofetil, methotrexate or cyclophosphamide, reported a high level of disease-related burden despite those treatments, according to research published in the Annals of Allergy, Asthma and Immunology.1
They not only reported severe disease symptoms, but also recurrent ares, impaired quality of life, reduced work productivity and compromised daily activities.
“The study period was prior to the availability of dupilumab (Dupixent, Sano Regeneron) in moderate-to-severe atopic dermatitis. However, it shows that the standard of care with currently available topical, oral systemic and phototherapies is clearly inadequate and that there is a need to improve control of atopic dermatitis in the United States,” says the study’s senior author Jonathan I. Silverberg, M.D., Ph.D., MPH, associate professor of dermatology, medical sciences and preventive medicine at the Feinberg School of Medicine, Northwestern University, Chicago.
Researchers conducted a longitudinal, prospective, observational study of atopic dermatitis patients who had been diagnosed in the last five years and had been prescribed systemic immunosuppressants, systemic corticosteroids or phototherapy. Participants completed a baseline paper survey, followed by web-based surveys at three, six, nine and 12 months, as well as shorter monthly web-based surveys in between.
Of the 801 adult participants analyzed, more than 66% said they had been diagnosed at 21 years or older.
1. Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381-388.e2.